Among the greatest valued personal business in biotech is lastly going public.

Moderna Therapies, a business establishing treatments based upon messenger RNA, raised more than $600 million in the greatest going public in biotech history, rates at $23 a share. Since Friday afternoon, it was trading down at $22 a share.

Learn More: The marketplace for biotech IPOs is red hot– here are the top 10 of 2018

Amongst the disclosures in Moderna’s declare the IPO was the payment for a few of the business’s magnates.

Visibly, Moderna’s president, Dr. Stephen Hoge, had a payment bundle worth nearly $24 million in 2017, according to the filing. That consisted of a wage of $542,308, a $4,400,000 perk, and $19,000,000 in stock alternatives.

In contrast, Moderna CEO St├ęphane Bancel made $6.8 million in 2017, while Moderna CFO Dr. Lorence Kim made $9.3 million.

Hoge, 42, signed up with Moderna in 2013 and ended up being president in2015 Hoge got his MD at the University of California, San Francisco and operated at McKinsey & Co. from 2005 to2012


Hoge’s payment bundle matches the incomes of CEOs like Pfizer’s Ian Read, who made $279 million in 2017 and Regeneron CEO Len Schleifer, who made $265 million that year.

Zach Tracer contributed reporting.

See likewise: